Skip to main content

Table 1 Baseline characteristics of 281 patients in development cohort and 160 patients in validation cohort (chi-square test and independent T test)

From: Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer

Origin of cohort

Training cohort

Validation cohort

P value

No. of Pts

281

160

 

No. of PCa (%)

141 (50.2)

86 (53.8)

0.68

No. of csPCa (%)

114 (40.6)

70 (43.8)

0.68

Age, median (IQR),

70 (63–77)

65 (62–75)

0.08

PSA, median (IQR), ng/ml

11.9 (6.8–25.5)

11.7 (7.4–26.7)

0.24

PV, median (IQR), ml

49.0 (35–73.4)

43.9 (36.5–59.4)

0.16

PSAD, median (IQR), ng/ml2

0.23 (0.12–0.55)

0.24 (0.13–0.43)

0.32

PIRADS v2

 1

6 (2.1)

0 (0.0)

0.07

 2

41 (14.6)

37 (23.1)

0.06

 3

75 (26.7)

22 (13.8)

0.01

 4

83 (29.5)

50 (31.3)

0.78

 5

76 (27.0)

51 (31.9)

0.43

  1. Pts patients, No. number, PCa prostate cancer, csPCa clinically significant prostate cancer, PSA prostate-specific antigen, IQR interquartile range, PV prostate volume, PSAD prostate-specific antigen density, PIRADS v2 Prostate Imaging Reporting and Data System version 2